INTRODUCTION {#sec1}
============

Water pipe (WP) smoking has become popular in European countries in recent years; the prevalence of regular use among individuals aged ≥15 years is estimated to be between 2 and 11%. \[[@ref1], [@ref2]\] In the pipe, a burning charcoal is used to heat tobacco mixed with molasses, which generates a smoke that is subsequently piped through a water bubbler and inhaled through a long, flexible tube. The smoke contains hot charcoal combustion products, which are drawn through the tobacco and inhaled \[[@ref3]\]. WP smoking thus carries tobacco-related health risks, including an increased risk for cardiorespiratory problems and cancer. We here report on a patient with secondary erythrocytosis due to WP smoking and hope to increase awareness among physicians for WP smoking as a possible cause of secondary erythrocytosis.

CASE REPORT {#sec2}
===========

A 27-year-old male patient was referred to us for evaluation of erythrocytosis of unknown origin, which was accompanied by frequent headaches. At presentation, haemoglobin (Hb) was 19.7 g/dl, and haematocrit (Hct) 54% (reference ranges: Hb 11--15 g/dl, Hct 32--45%) (Fig. [1](#f1){ref-type="fig"}). With the exception of hypertonus and obesity (weight 116 kg, height 190 cm), he had no relevant medical history, was not taking medications and denied use of herbal remedies, steroids, recreational drugs or androgen hormone substitutions. His family medical history was negative for haematological diseases or malignancies. Physical examination revealed plethora of the cheeks and a muscular body type. Extensive diagnostic analyses before referral had excluded diagnosis of polycaethemia vera, and presence of mutations in a large panel of genes associated with erythroid abnormalities and malignancies (Table [1](#TB1){ref-type="table"}). Serum erythropoietin levels were normal, and histological and cytological analyses of the bone marrow (BM) indicated a reactive process with hyperplastic erythropoiesis. Secondary erythrocytosis due to altered hormone status was excluded as cortisol, testosterone and thyroid-stimulating hormone (TSH) serum levels were normal. The patient denied cigarette smoking but reported regular WP smoking since the age of 14 years. At the time of presentation he was smoking 3--5 sessions daily, mainly indoors in the evenings. We determined his carboxy-haemoglobin (CO-Hb) levels \~2 hours after his last WP session, which were elevated to 15.4 (reference range of CO-Hb among non-smokers: 0.5--1.5%). A transthoracic echocardiogram and pulmonary function tests were normal (Fig. [1](#f1){ref-type="fig"}). Four weeks after complete WP cessation the Hb concentration and Hct levels had returned to normal (Fig. [1](#f1){ref-type="fig"}). Because he was first unwilling to desist completely, the patient subsequently resumed moderate WP use outdoors. During the following 4 weeks his Hb and Hct levels again increased (Fig. [1](#f1){ref-type="fig"}), once more returning to normal after complete cessation.

![Hb and CO-Hb over-time depending on the WP smoking habit. WP smoking intensity is indicated in the figure.](omz027f1){#f1}

Discussion {#sec3}
==========

Secondary erythrocytosis can result from a wide range of underlying disorders. Most cases are caused by chronic hypoxia due to cardiac and/or pulmonary diseases, frequently associated with smoking; other common causes include the use of anabolic steroids or diuretics \[[@ref5]\]. We only identified three case reports in the literature, in which the diagnostic evaluation of an erythrocytosis identified long-term WP smoking as the cause \[[@ref6], [@ref7], [@ref8]\].

###### 

Laboratory and mutation data

  Laboratory data                                                   Result
  ----------------------------------------------------------------- ------------
  White blood cell count, x10^6^/L (3.9--9.8)                       6.1
  Platelets, x10^6^/L (146--328)                                    230
  Haemoglobin, g/dL (13.5--17.6)                                    19.7
  Haematocrit, % (39.6--50.6)                                       54.1
  Erythropoietin, mU/mL (4.3--29)                                   16.1
  LDH, U/L (135--214)                                               195
  Ferritin, ng/mL (15--150)                                         142
  Cortisol, nmol/L (133--537)                                       195
  Testosterone, nmol/L (8.64--29.0)                                 13.3
  Thyroid-stimulating hormone, μU/ml (0.27--4.20)                   1.04
  Met-Hb, % (0--1.5)                                                0.9
  CO-Hb, % (0.5--1.5)                                               15.4
  Mutation analyses                                                 
  *BCR-ABL*                                                         negative
  *JAK2* exons 12 + 14 (V617F)                                      wild-type
  *CALR* exon 9                                                     wild-type
  *MPL* exon 10                                                     wild-type
  *ASXL1* exon 13                                                   wild-type
  *IDH2* exon 4                                                     wild-type
  *SRSF2* exon 1                                                    wild-type
  *TET2* exons 3--11                                                wild-type
  *TP53* exons 2--8                                                 wild-type
  *U2AF1* exons 2 + 6                                               wild-type
  *EGLN (PHD2)* exons 2--3                                          wild-type
  *EPAS1 (HIF2A)* exon 12                                           wild-type
  *EPOR* exon 8                                                     wild-type
  *VHL* exons 1--3                                                  wild-type
  Pulmonary function                                                
  Vital capacity (VC), L                                            5.7 (91%)
  Forced expiratory volume in 1 second (FEV1), L                    4.8 (97%)
  FEV1/VC, %                                                        84 (102%)
  Diffusing capacity of the lung for CO (corrected), mmol/min/kPa   10.5 (79%)

Notes: For laboratory data, the respective local reference range is provided in parentheses. The laboratory data were assessed at time of referral. The mutation data were assessed before referral from bone marrow or peripheral blood.

A likely cause for a secondary erythrocytosis in heavy WP smokers is chronic elevation of CO-Hb. A study on the effects of cigarette and WP smoking showed that WP produced a 3.75-fold greater elevation in peak CO-Hb levels and was associated with a 56-fold greater amount of smoke inhaled \[[@ref9]\]. In another study, a single 30-minute WP session resulted in significant increase of CO-Hb level and increased blood pressure, heart and respiratory rates; importantly elevated CO-Hb levels and respiratory rates were also found in passive smokers \[[@ref10]\].

Acute carbon monoxide (CO) poisoning due to WP smoking is well known and presents with nausea and loss of consciousness; chronic poisoning normally induces fatigue, irritability, impaired concentration and reduced physical status \[[@ref3], [@ref7]\]. The effects of chronic WP smoking on the haematopoietic system are less well described. A rat model of WP smoking showed a significant increase of Hb and Hct in WP smoking rats compared to the control group \[[@ref4]\].

CO is a colourless and odourless gas, generated by incomplete combustion of hydrocarbons, in this case the burning charcoal. Following inhalation, CO diffuses across the alveolar membrane and reversibly binds heme, forming CO-Hb. The affinity of CO to Hb is 200-fold higher than that of oxygen. Consequently, tissue oxygen delivery is impaired. In the BM, chronic cellular hypoxia increases expression of the transcription factor HIF-1a by preventing its active degradation. HIF-1a increases transcription of erythropoietin, which stimulates erythropoiesis, ultimately causing erythrocytosis \[[@ref2]\].

Chronic CO-Hb elevation and induction of secondary erythrocytosis does not constitute the only health risk associated with WP smoking. Following consumption, no differences in peak nicotine plasma concentrations were observed between WP and cigarette smokers. However, 30 to 45 minutes after smoking, mean plasma nicotine concentrations were significantly higher in individuals smoking WP (mean smoking time: 43 minutes) than in cigarette smokers (mean smoking time: 6 minutes), suggesting that WP smoking results in a prolonged exposure to nicotine \[[@ref9]\]. Subjective effects, including those relevant for dependence, were comparable in strength but lasted partly longer among WP smokers \[[@ref9]\].

In Western countries the term 'smoking' often exclusively refers to cigarette smoking. Therefore, other smoking habits have to be explicitly sought out when taking a medical history. WP smokers often fail to mention their habit, as they consider it harmless, following a common misbelief that the water cleans the smoke of toxic substances.

Among the previous reports, our case stands out as we were able to observe dynamic changes in the blood counts paralleling the intensity of WP usage. Upon cessation, Hb normalized rapidly, whereas it rose again when the patient resumed. At last follow-up, blood parameters had again returned to normal within a few weeks of abstinence.

In conclusion, we report WP smoking as a cause of secondary erythrocytosis, thereby raising awareness among physicians to obtain the relevant history and consider this cause especially when evaluating young adults. Given the increased popularity of WP smoking haematological effects may be more prevalent than the current literature suggests.
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